HEPA · ISSUER CIK 1583771
Hepion Pharmaceuticals, Inc.
Between Jul 31, 2026 and Oct 28, 2026, 6 Hepion Pharmaceuticals, Inc. insiders reported $835K of open-market purchases and $0.00 of sales on SEC Form 4. The largest buyer was LoPriore Vincent S (Executive Chairman, Director), with $500K.
↗6 insiders filed
Original Form 4 filings from Jul 31, 2026 to Oct 28, 2026. No open-market sales in the window.
$835KInsider buying
$0.00Insider selling
+$835KNet open-market
Oct 2, 2026Latest filing
| Ticker | Insider | Type | Owned | ||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|
| Oct 2, 202616:30 | Sep 29, 2026 | HEPA | Director | P · Buy | $0.05 | +200,000 | 200,000 | New | +$10K | -47.4% | +200.0% |
| Aug 12, 202621:43 | Aug 3, 2026 | HEPA | Director | P · BuyLate 9d | $0.05 | +500,000 | 500,000 | New | +$25K | -47.4% | +200.0% |
| Aug 12, 202621:41 | Aug 3, 2026 | HEPA | Interim CEO, Director | P · BuyLate 9d | $0.05 | +2,000,000 | 3,250,000 | +160% | +$100K | -47.4% | +200.0% |
| Aug 12, 202621:39 | Aug 3, 2026 | HEPA | Director | P · BuyLate 9d | $0.05 | +2,000,000 | 3,250,000 | +160% | +$100K | -47.4% | +200.0% |
| Aug 12, 202621:36 | Aug 3, 2026 | HEPA | Chief Operating Officer, Director | P · BuyLate 9d | $0.05 | +2,000,000 | 3,250,000 | +160% | +$100K | -47.4% | +200.0% |
| Aug 12, 202621:34 | Aug 3, 2026 | HEPA | Executive Chairman, Director | P · BuyLate 9d | $0.05 | +10,000,000 | 16,250,000 | +160% | +$500K | -47.4% | +200.0% |